Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

Get insights on Corvus Pharmaceuticals' Q2 2025 earnings call. Learn about soquelitinib's clinical progress, Phase II trial plans, and financial strategies.

USA: Atopic eczema (AE), including AE severity, is linked with a decreasing lymphocyte count, regardless of the use of the ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Eli Lilly (LLY) recently introduced EBGLYSS through Senderra Specialty Pharmacy, targeting patients with atopic dermatitis, ...

Long-term exposure to pollutants was linked to higher psoriasis risk, especially in people with genetic predispositions.